Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Myeloproliferative Disorders 2Myelodysplastic Syndromes 2beta-Thalassemia 1Leukemia, Myeloid, Acute 1

Interventions

fludarabine 15Specimen Handling 14Cyclophosphamide 13Biopsy 12fludarabine phosphate 10Cytarabine 10Mycophenolic Acid 9Melphalan 9Busulfan 9venetoclax 8Whole-Body Irradiation 8Tacrolimus 8decitabine and cedazuridine drug combination 7Granulocyte Colony-Stimulating Factor 7Injections 6Cyclosporine 6Azacitidine 6Stem Cell Transplantation 5Sirolimus 5Filgrastim 5X-Rays 4Peripheral Blood Stem Cell Transplantation 4Idarubicin 4CPX-351 4ruxolitinib 3Thiotepa 3Magnetic Resonance Spectroscopy 3Hematopoietic Stem Cell Transplantation 3Decitabine 3treosulfan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × luspatercept × 30 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡